After finishing at $0.74 in the prior trading day, Citius Pharmaceuticals Inc (NASDAQ: CTXR) closed at $0.72, down -2.20%. In other words, the price has decreased by -$0.0162 from its previous closing price. On the day, 1086050 shares were traded. CTXR stock price reached its highest trading level at $0.7998 during the session, while it also had its lowest trading level at $0.7000.
Ratios:
Our goal is to gain a better understanding of CTXR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.06 and its Current Ratio is at 5.06. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on November 30, 2021, initiated with a Buy rating and assigned the stock a target price of $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTXR now has a Market Capitalization of 114.58M and an Enterprise Value of 94.66M.
Stock Price History:
Over the past 52 weeks, CTXR has reached a high of $1.71, while it has fallen to a 52-week low of $0.60. The 50-Day Moving Average of the stock is 0.7160, while the 200-Day Moving Average is calculated to be 0.8615.
Shares Statistics:
The stock has traded on average 645.07K shares per day over the past 3-months and 666.57k shares per day over the last 10 days, according to various share statistics. A total of 158.86M shares are outstanding, with a floating share count of 146.79M. Insiders hold about 7.74% of the company’s shares, while institutions hold 16.96% stake in the company. Shares short for CTXR as of Feb 29, 2024 were 11.86M with a Short Ratio of 18.39, compared to 11.61M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.46% and a Short% of Float of 8.08%.
Earnings Estimates
Its stock is currently analyzed by 2 different market analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.05 and a low estimate of -$0.06, while EPS last year was -$0.07. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.21 and -$0.21 for the fiscal current year, implying an average EPS of -$0.21. EPS for the following year is $0.12, with 2 analysts recommending between $0.16 and $0.09.
Revenue Estimates
Based on 2 analysts’ estimates, the company’s revenue will be $83.59M in the next fiscal year. The high estimate is $121.3M and the low estimate is $45.89M. The average revenue growth estimate for next year is up 35.40% from the average revenue estimate for this year.
